Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Researchers Use Physics Technology to Develop Rapid Antigen COVID-19 Test

By LabMedica International staff writers
Posted on 10 Nov 2020
Researchers have adapted technology that is typically used for physics applications to create a rapid antigen COVID test that has been able to detect viral proteins in minutes with high accuracy.

Currently, PCR-, antigen-, and antibody-based technologies have been at the forefront in the development of COVID testing. However, scientists are looking into other technologies not usually used in the life sciences in order to improve the detection of the virus. Researchers from the Department of Materials Science and Engineering at the Massachusetts Institute of Technology (Cambridge, MA, USA) have developed a test called TriboSense One that does not have an optical readout for detecting viruses like many current tests on the market, but instead provides a mechanical readout to assess the strength of biomolecular interactions, looking at friction to detect a sample's molecular interactions and confirm the presence of the virus in very small concentrations.

The instrument measures how molecules in saliva affect the motion of sensing beads with magnetic properties to determine whether SARS-CoV-2 viruses are present or not. The beads and the saliva are mixed together during sample prep. Currently, the test detects the spike protein of the virus, but the magnetic sensing particles can also be customized to stick to different types of proteins, for example the nucleocapsid protein of SARS-CoV-2, which the researchers are also pursuing. Once the saliva sample is collected, the consumer's job is quite simple, consisting mostly of pipetting the sample into the solution. The technology was originally created to measure protein-protein, protein-DNA, DNA-DNA and other biomolecular interactions. Eventually, the team wants to expand testing to other diseases, but the focus now is on COVID-19. The testing system could potentially benefit point-of-care settings because of its small size and portability. The test is also inexpensive; while it costs around USD 5-6 right now, at scale it could even cost as little as USD 3.

"We had to go from scratch," said MIT Professor Alfredo Alexander-Katz. "We had never worked on viruses … and we adapted the technology to be able to do this."

Related Links:
Massachusetts Institute of Technology


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory QC Panel
Assayed Respiratory Control Panel
New
Centrifuge
Hematocrit Centrifuge 7511M4
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.